Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xuanfei Jiangzhuo Decoction is a traditional Chinese medicine (TCM) composite formula being investigated for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD) triggered by influenza. Derived from the classical formulas *Maxing Shigan Tang* and *Shengjiang San*, it is designed to alleviate respiratory symptoms such as cough and dyspnea while potentially reducing the risk of secondary bacterial infections. The decoction is typically administered orally as a liquid. It is currently being studied in a prospective, real-world cohort study led by Tianjin Medical University to evaluate its efficacy in promoting clinical remission and its impact on gut health and systemic inflammation in older adults.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Xuanfei Jiangzhuo Decoction.